Study wrapper · #592
Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE-/- mice.
Editor's note
In ApoE-knockout mice on a high-fat diet, researchers reported that hexarelin, a synthetic growth hormone secretagogue, given for three months was associated with improved lipid profiles, smaller atherosclerotic plaques, and reduced macrophage uptake of oxidized LDL. The proposed mechanism is suppression of the LOX-1/NF-kappaB pathway, supported by parallel findings in cultured macrophages. This aligns with hexarelin's wider anti-inflammatory vascular literature. The caveats are familiar: the ApoE-knockout mouse is an aggressive, artificial model of atherosclerosis, group sizes are modest, and the authors' description of hexarelin as an 'anti-atherosclerosis drug' overstates what a single rodent study supports. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Researchers studied hexarelin, a lab-made peptide, in mice genetically prone to atherosclerosis (fatty buildup in arteries) and fed a high-fat diet for three months. Compared with untreated mice, those given hexarelin had healthier blood-fat levels (lower total cholesterol, triglycerides, and LDL; higher HDL) and smaller artery plaques. In both the animals and in immune cells studied separately, hexarelin reduced the uptake of oxidized LDL cholesterol and calmed an inflammation-driving pathway (LOX-1/NF-kappaB). The authors conclude hexarelin slowed plaque development by improving blood fats and reducing inflammatory cholesterol uptake. The abstract reports no adverse events. These are preclinical findings in mice; human studies would be needed before drawing clinical conclusions.